Minnetronix client Sona Nanotech announced that it has submitted a provisional patent application with the United States Patent and Trademark Office for its proprietary photothermal light device, entitled, “ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY.” A prototype of Sona’s medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860-nanometer wavelength high-intensity infrared laser light. The device has been designed for use with Sona’s patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for Sona’s ongoing pre-clinical efficacy study of its Targeted Hyperthermia Therapy cancer treatment at Dalhousie University in Halifax, Nova Scotia, Canada.
Experience designing and developing light delivery devices for a variety of applications enabled the Minnetronix team to rapidly create a prototype that meets Sona’s specific intensity and delivery system constraints. Finding a light delivery solution with commercialization in mind, even for pre-clinical studies, reduces the risk of architectural system changes in the final device development stages, preventing delays. Minnetronix is proud to partner with Sona in developing this technology and creating better outcomes for patients.
To read more on this announcement Click Here
About Sona Nanotech Inc.
Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (“CTAB”) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
About Minnetronix Medical
Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development, and manufacturing partner to leading device companies around the world. Today, through lifecycle efficiency, opportunity realization, and increased utility, the company creates value in key technology segments that include optical systems, RF energy, fluid and gas management, and stimulation & active wearables. From design and manufacturing services to whole product solutions, Minnetronix has the expansive industry insight and intentional technical acumen to deliver better medical devices to market, faster.